959 related articles for article (PubMed ID: 27098723)
1. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
2. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
[TBL] [Abstract][Full Text] [Related]
3. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
[TBL] [Abstract][Full Text] [Related]
5. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
[TBL] [Abstract][Full Text] [Related]
6. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
[TBL] [Abstract][Full Text] [Related]
7. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Ramos S; Staines D; Marshall-Gradisnik S
J Transl Med; 2015 Sep; 13():299. PubMed ID: 26370228
[TBL] [Abstract][Full Text] [Related]
9. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
Brenu EW; van Driel ML; Staines DR; Ashton KJ; Ramos SB; Keane J; Klimas NG; Marshall-Gradisnik SM
J Transl Med; 2011 May; 9():81. PubMed ID: 21619669
[TBL] [Abstract][Full Text] [Related]
10. Immune and hemorheological changes in chronic fatigue syndrome.
Brenu EW; Staines DR; Baskurt OK; Ashton KJ; Ramos SB; Christy RM; Marshall-Gradisnik SM
J Transl Med; 2010 Jan; 8():1. PubMed ID: 20064266
[TBL] [Abstract][Full Text] [Related]
11. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Rivas JL; Palencia T; Fernández G; García M
Front Immunol; 2018; 9():1028. PubMed ID: 29867995
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome.
Eaton-Fitch N; du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
Syst Rev; 2019 Nov; 8(1):279. PubMed ID: 31727160
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell lytic activity and CD56(dim) and CD56(bright) cell distributions during and after intensive training.
Suzui M; Kawai T; Kimura H; Takeda K; Yagita H; Okumura K; Shek PN; Shephard RJ
J Appl Physiol (1985); 2004 Jun; 96(6):2167-73. PubMed ID: 14752119
[TBL] [Abstract][Full Text] [Related]
15. Role of chemokines in the biology of natural killer cells.
Maghazachi AA
Curr Top Microbiol Immunol; 2010; 341():37-58. PubMed ID: 20369317
[TBL] [Abstract][Full Text] [Related]
16. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.
Morandi F; Horenstein AL; Chillemi A; Quarona V; Chiesa S; Imperatori A; Zanellato S; Mortara L; Gattorno M; Pistoia V; Malavasi F
J Immunol; 2015 Aug; 195(3):965-72. PubMed ID: 26091716
[TBL] [Abstract][Full Text] [Related]
17. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
Voss SD; Daley J; Ritz J; Robertson MJ
J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
[TBL] [Abstract][Full Text] [Related]
18. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
19. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
20. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]